$1.04
-0.05-4.59%
最終更新: Nov 6, 7:57 PM
Benzinga
Benzinga
Benzinga
土曜日, 11 07
Benzinga
© 2026 Benzinga | All Rights Reserved
The average analyst price target for Allogene Therapeutics is $7.68, 624.5% above the current price. Of 18 analysts, 12 rate it Buy and 6 Hold. Targets range from $3.85 to $14. The latest change came on Apr 16, 2026, when JP Morgan upgraded Allogene Therapeutics from Underweight to Neutral.
Price Target Range — 11 Quarters
Analyst Consensus — 18 Analysts
Rating Trend — Last 9 Months